HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2428 Mepolizumab (Anti-IL-5) Mepolizumab (Anti-IL-5) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. MW: 145.5 kD. Aug 10 2023
A2430 Pascolizumab (Anti-IL-4) Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD. Aug 10 2023
A2431 Talacotuzumab (Anti-IL-3Ra / CD123) Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD. Aug 10 2023
A2432 Itepekimab (Anti-IL-33) Itepekimab (Anti-IL-33) is a monoclonal antibody against IL-33. Itepekimab reduces airway inflammation and related tissue damage in previous clinical studies. MW: 145.5 kD. Aug 10 2023
A2433 Nemolizumab (Anti-IL-31Ra) Nemolizumab (Anti-IL-31Ra) is a humanized monoclonal antibody, targeting IL-31Ra. It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 KD. Aug 10 2023
A2434 Daclizumab (Anti-IL-2Ra / CD25) Daclizumab (Anti-IL-2Ra / CD25) is a recombinant monoclonal antibody interleukin-2 receptor antagonist. MW:145.5 KD. Aug 10 2023
A2435 Basiliximab (Anti-IL-2Ra / CD25) Basiliximab (Anti-IL-2Ra / CD25) is a recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. MW:145.58 KD. Aug 10 2023
A2437 Tildrakizumab (Anti-IL-23a) Tildrakizumab (Anti-IL-23a) is a humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. MW:145.5 KD. Aug 10 2023
A2438 Guselkumab (Anti-IL-23) Guselkumab (Anti-IL-23) is a recombinant human IgG1 monoclonal antibody. It targets the key IL-23 and inhibits the production of cytokines lying downstream of the IL-23 signaling pathway and can be used for reatment of psoriatic arthritis, Crohn's disease, and ulcerative colitis. MW : 145.5 KD. Aug 10 2023
A2439 Anti-IL-22Ra Anti-IL-22Ra is an affinity isolated polyclonal antibody, targeting IL-22R. It is used in the treatment of psoriasis, psoriatic arthritis, atopic dermatitis. MW :145.5 KD. Aug 10 2023
A2440 Fezakinumab (Anti-IL-22) Fezakinumab (Anti-IL-22) is a monoclonal antibody targeting IL-22. It can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis. MW :145.5 KD. Aug 10 2023
A2441 Fletikumab (Anti-IL-20) Fletikumab (Anti-IL-20) is a monoclonal antibody, targeting IL-20. It can be used for inflammation research, such as rheumatoid arthritis and psoriasis. MW : 145.5 KD. Aug 10 2023
A2442 Spesolimab (Anti-IL-1RL2 / IL-36R) Spesolimab (Anti-IL-1RL2 / IL-36R) is an humanized antagonistic monoclonal antibody targeting IL-36 receptor. It can be used for treatment of palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP). MW : 145.5 KD. Aug 10 2023
A2443 Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. It has the potential for chronic obstructive pulmonary disease (COPD), asthama treatment. MW :145.5 KD Aug 10 2023
A2444 Nidanilimab (Anti-IL-1RAP / IL-1R3) Nidanilimab (Anti-IL-1RAP / IL-1R3) is a fully humanized monoclonal antibody targeting IL1RAP and blocks IL1α and IL1β signaling. It also stimulates the immune system to destroy tumour cells. It can be used in treatment of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). MW :143.56 KD. Aug 10 2023
A2445 Anti-IL-1R1 / CD121a Anti-IL-1R1 / CD121a is a fully humanized monoclonal antibody that targets interleukin-1 (IL-1), inhibiting the activity of IL-1a and IL-1b. It can be beneficial in treatment of osteoarthritis (OA) and rheumatoid arthritis. MW :145.5 KD. Aug 10 2023
A2446 Canakinumab (Anti-IL-1b) Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD. Aug 10 2023
A2447 Bermekimab (Anti-IL-1a) Bermekimab (Anti-IL-1a) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). It prevents tumour-related inflammation. MW :145.5 KD. Aug 10 2023
A2448 Anti-IL-18 Anti-IL-18 is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). MW :150 KD. Aug 10 2023
A2450 Anti-IL-17c Anti-IL-17c is a fully humanized recombinant IgG1 monoclonal antibody targeting IL-17C. It can be used in a clinical treatment of atopic dermatitis. MW :145.5 KD. Aug 10 2023